Hexima Ltd (HXL) AI Stock Analysis

• Market Cap: AU$2.17M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -2.27
• Revenue Growth: N/A
• EPS Growth: 46.43%
• Country: AU
• Employees: N/A
• Sector: Financial
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 167,039,630
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.09
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: AU$0.01 ▲(20.00% Upside)

The score is primarily driven by weak financial performance—recurring losses, negative cash flow, and revenue falling to near-zero—partially offset by a low-debt balance sheet. Technicals show some upward bias versus moving averages but with extreme/erratic momentum signals, while valuation is pressured by a negative P/E and no dividend support.

Positive Factors

Conservative Leverage

A low-debt balance sheet reduces financial risk and refinancing pressure, providing stability and flexibility in strategic planning.

Shareholder Support

Strong shareholder support at the AGM indicates confidence in management and strategic direction, potentially aiding future governance.

Strategic Opportunities

Exploring strategic opportunities can unlock shareholder value and improve financial strategy, enhancing long-term business prospects.

Negative Factors

Revenue Volatility

Extreme revenue volatility and near-zero levels indicate weak commercialization, posing challenges to achieving sustainable growth.

Negative Cash Flow

Persistent negative cash flow highlights a cash-burning profile, necessitating external funding and impacting long-term financial health.

Clinical Setbacks

Clinical setbacks can delay product development and commercialization, affecting the company's ability to generate future revenue.

Hexima Ltd Business Overview & Revenue Model

Company Description

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.

How the Company Makes Money

Hexima Ltd generates revenue through the commercialization of its proprietary plant-derived protein technologies. The company's key revenue streams include the sale of licensed products to agricultural producers and pharmaceutical companies, as well as collaboration and licensing agreements with industry partners. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Hexima may engage in research and development collaborations that provide financial support and access to new markets. The company also benefits from government grants and subsidies aimed at promoting innovation in biotechnology.

Hexima Ltd Financial Statement Overview

Summary

Hexima Ltd faces significant financial challenges, with consistent operating losses and negative cash flows. While the balance sheet is supported by strong equity and a solid cash position, the company struggles with profitability and sustainable revenue growth. Strategic improvements in revenue generation and cost management are essential for future stability.

Income Statement

Hexima Ltd has experienced negative revenue growth and consistent losses over the past years. Net profit margin and other profitability metrics are negative, indicating ongoing financial challenges. The company needs to improve revenue generation and cost management to stabilize its financial health.

Balance Sheet

The balance sheet shows a strong equity position with no debt, resulting in a favorable debt-to-equity ratio. However, the company has been unable to generate positive returns on equity due to persistent losses, affecting its ability to create shareholder value.

Cash Flow

Operating cash flow has been negative, reflecting operational inefficiencies. Although Hexima Ltd has maintained a strong cash position, free cash flow remains negative, indicating challenges in generating cash from operations despite limited capital expenditures.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	1.48M	5.81M	4.08M
Gross Profit	0.00	0.00	0.00	1.47M	5.67M	3.93M
EBITDA	0.00	0.00	-995.54K	-3.08M	-15.21M	-10.34M
Net Income	-503.83K	-503.83K	-933.87K	-1.92M	-10.02M	-6.87M
Balance Sheet
Total Assets	1.56M	1.56M	2.27M	2.96M	10.75M	8.58M
Cash, Cash Equivalents and Short-Term Investments	1.54M	1.54M	2.23M	2.19M	3.96M	3.42M
Total Debt	0.00	0.00	0.00	0.00	0.00	32.00K
Total Liabilities	40.70K	40.70K	248.67K	174.45K	6.19M	5.53M
Stockholders Equity	1.52M	1.52M	2.02M	2.78M	4.57M	3.05M
Cash Flow
Free Cash Flow	-637.19K	-637.19K	-161.90K	-1.76M	-9.76M	-5.79M
Operating Cash Flow	-637.19K	-637.19K	-161.90K	-1.76M	-9.76M	-5.79M
Investing Cash Flow	46.79K	46.79K	98.00K	38.97K	-1.80K	-903.00
Financing Cash Flow	-100.00K	-100.00K	100.00K	-3.66K	10.34M	7.90M

Hexima Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.

Hexima Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
VBS	49 Neutral	AU$6.95M	-3.89	-289.05%	―	―	24.09%
AVE	44 Neutral	AU$36.73M	-9.09	-143.71%	―	306.88%	―
ANR	41 Neutral	AU$4.39M	-1.46	-205.70%	―	―	1.03%
HXL	40 Underperform	AU$2.17M	-4.33	-28.49%	―	―	46.43%
CMB	40 Underperform	AU$10.57M	-1.79	-166.70%	―	―	―
1AD	37 Underperform	AU$13.77M	-1.61	-628.72%	―	―	31.87%

Hexima Ltd Corporate Events

Hexima Ltd Announces Successful AGM Results

Hexima Ltd announced the results of its 2025 Annual General Meeting, where all resolutions, including the remuneration report and the re-election of Mr. Phillip Hains, were passed by a poll. The successful passing of these resolutions indicates strong shareholder support and is likely to positively impact the company’s governance and strategic direction.

Hexima Ltd Outlines Future Amidst Clinical Setbacks

Hexima Ltd’s Chair addressed the company’s current position and future direction at the 2025 Annual General Meeting. After disappointing clinical trial results for its onychomycosis treatment, Hexima has shifted focus, transferring intellectual property rights and exploring potential value from its listed structure. The company holds contingent assets through royalty agreements and a license with Corteva Inc., but remains suspended from ASX trading, with no active operations and limited cash reserves.

Hexima Limited Explores Strategic Opportunities Amid Quarterly Financial Update

Hexima Limited reported a cash balance of $1.44 million for the quarter ending September 30, 2025, with net cash usage of $95,000 in operating activities. The company is exploring strategic opportunities, including a potential capital return to shareholders, which could impact its financial strategy and shareholder value.

Hexima Limited Announces 2025 AGM Details

Hexima Limited, listed on the ASX under the ticker HXL, has announced the details of its upcoming 2025 Annual General Meeting (AGM). The meeting is scheduled to take place on November 27, 2025, at the offices of QR Lawyers in Melbourne, Australia. This announcement, authorized by the Board of Hexima Limited, provides stakeholders with the necessary information to participate in the AGM, reflecting the company’s commitment to transparency and shareholder engagement.